deltatrials
Terminated PHASE2 NCT00157248

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)

Sponsor: Boehringer Ingelheim

Conditions Atrial Fibrillation Stroke
Interventions dabigatran etexilate
Updated 6 times since 2017 Last updated: May 8, 2014 Started: Dec 31, 2003 Primary completion: Jan 31, 2009

This PHASE2 trial investigates Atrial Fibrillation and Stroke and is currently terminated or withdrawn. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark, Aarhus C, Denmark, Amstelveen, Netherlands, Amsterdam, Netherlands, Apeldoorn, Netherlands, Assen, Netherlands, Baltimore, United States, Brædstrup, Denmark, Den Helder, Netherlands, Ede, Netherlands and 38 more location s